Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 55 matches for

U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.

Icosphere Biosciences appoints Dr John Beadle as Non-Executive Director

Dr Beadle brings a remarkable track record of leading biotechnology companies, guiding teams from early discovery through to successful clinical translation.

U-Ploid Biotechnologies wins Femtech competition award at the Carlos Simón Foundation for research in women’s health

U‑Ploid, a biotechnology company developing first-in-class therapeutics to tackle age-related infertility, has been awarded the Femtech Competition Award at the Femtech Pitch Showcase & Competition organised by the Carlos Simón Foundation for Research in Women’s Health, a leading institution advancing scientific excellence in reproductive medicine.

Oxford Cancer Analytics secures new space at Inventa to accelerate diagnostic innovation

Oxford Cancer Analytics (OXcan), a fast-scaling diagnostics company, has committed to a new lease of 2,400 square feet at Mission Street and BGO’s Inventa building in Oxford’s West End. OXcan is continuing its growth trajectory, moving from the BioEscalator to Inventa and joining a growing number of innovation companies in the emerging central cluster.

U-Ploid presents first Lyvanta™ data demonstrating reduction of aneuploidy in aged oocytes at ASRM 2025

U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.

Exogene Graduates from the BioEscalator

We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.

Simon Meier will be joining Oxford Cancer Analytics (OXcan) as Incoming Interim CEO

Simon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.

Dr.Peter Jianrui Liu to step down as CEO of Oxford Cancer Analytics Ltd (OXcan)

Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company’s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company’s development and success as an advisor.

Oxford Cancer Analytics featured in CTV News

In the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.

Green is the new gold: Infinitopes awarded gold LEAF accreditation

Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.

Congratulations Alethiomics, the BioEscalator’s most recent graduate

We’re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.

Innovate UK awards Icosphere Biomedical Catalyst grant

Icosphere Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Develop Breakthrough Gene Therapy Vector Manufacturing Technology.

Innovate UK feature Infinitopes in recent case study

Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.

U-Ploid Biotechnologies featured in EQT Foundation's 25 Scientific Founders Pushing the Frontiers of Impact 2025 report

U-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.

Welcome, Sandbox Bioscience, to the BioEscalator Community!

We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.

U‑Ploid Biotechnologies selected for prestigious Merck Corporate Accelerator Programme to advance women’s health innovation

U‑Ploid, a biotechnology company developing first-in-class therapeutics to address age-related infertility, today announced its selection for the inaugural Merck Corporate Accelerator. The programme, launched by EMD Serono in partnership with the Society for Innovation and Startups (SIS), is designed to support breakthrough innovation in women’s health by providing funding, expert mentorship, and access to Merck’s global network of scientific and clinical leaders.

Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer

Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company’s lead ‘off-the-shelf’ cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company’s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).

Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age

Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the main contributing factors to infertility and is known to deteriorate rapidly with increasing female age. This research collaboration has the potential to validate novel therapeutics and offer hope to millions struggling to conceive.

Dr Mary Vinson joins the U-Ploid as Clinical Development Advisor

Dr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.

Infinitopes strengthens Board with two biotech leaders to advance precision immunotherapies into the clinic

Infinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.

Entelo Bio ushering in new ways of doing science

Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.

Load More

Similar stories